Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Baxter
Express Scripts
McKesson
Johnson and Johnson

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Patent: 5,545,405

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 5,545,405
Title: Method for treating a mammal suffering from cancer with a cho-glycosylated antibody
Abstract:The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
Inventor(s): Page; Martin J. (Beckenham, GB)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:08/335,401
Patent Claims:see list of patent claims

Details for Patent 5,545,405

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 5,545,405

Country Patent Number Publication Date
South Africa 9108248 Apr 16, 1993
United States of America 2002182208 Dec 05, 2002
United States of America 2003035799 Feb 20, 2003
United States of America 2004228857 Nov 18, 2004
United States of America 2008279852 Nov 13, 2008
United States of America 5545403 Aug 13, 1996
United States of America 5545404 Aug 13, 1996
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
McKinsey
Johnson and Johnson
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.